In vitro antimicrobial susceptibility data of global meropenem-resistant Acinetobacter baumannii isolates causing pneumonia: Data from the Antimicrobial Testing Leadership and Surveillance Program, 2014–2021, and re-estimations of susceptibility breakpoints and appropriate dosages of important antibiotics for pneumonia treatment
ABSTRACT: Objectives: To evaluate the susceptibility of globally pneumonia-causing meropenem-resistant (MEM-R) Acinetobacter baumannii isolates against important antibiotics and estimate appropriate dosages of indicated antibiotics. Methods: We extracted the 2014–2021 Antimicrobial Testing of Leade...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-03-01
|
| Series: | Journal of Global Antimicrobial Resistance |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213716524000249 |
| _version_ | 1797249167971581952 |
|---|---|
| author | Shun-Chung Hsueh Yu-Tsung Huang Wen-Chien Ko I-Min Liu Po-Chuen Hsieh Shio-Shin Jean |
| author_facet | Shun-Chung Hsueh Yu-Tsung Huang Wen-Chien Ko I-Min Liu Po-Chuen Hsieh Shio-Shin Jean |
| author_sort | Shun-Chung Hsueh |
| collection | DOAJ |
| description | ABSTRACT: Objectives: To evaluate the susceptibility of globally pneumonia-causing meropenem-resistant (MEM-R) Acinetobacter baumannii isolates against important antibiotics and estimate appropriate dosages of indicated antibiotics. Methods: We extracted the 2014–2021 Antimicrobial Testing of Leadership Surveillance database regarding the susceptibility of MEM-R A. baumannii isolates causing pneumonia against important antibiotics. The susceptibility and carbapenemase-encoding gene (CPEG) data of pneumonia-causing MEM-R A. baumannii isolates from patients hospitalized in intensive care units of five major regions were analyzed. The susceptibility breakpoints (SBP) recommended by the Clinical and Laboratory Standards Institute (CLSI) in 2022, other necessary criteria [SBP of MIC for colistin, 2 mg/L, in the CLSI 2018; and cefoperazone-sulbactam (CFP-SUL), 16 mg/L], and the pharmacokinetic and pharmacodynamic data of indicated antibiotics were employed. Results: Applying the aforementioned criteria, we observed the susceptible rates of colistin, minocycline, and CFP-SUL against the pneumonia-causing MEM-R A. baumannii isolates globally (n = 2905) were 93.2%, 69.1%, and 26.3%, respectively. Minocycline was significantly more active in vitro (MIC ≤4 mg/L) against the pneumonia-causing MEM-R A. baumannii isolates collected from North and South America compared to those from other regions (>90% vs. 58–72%). Additionally, blaOXA-23 and blaOXA-72 were the predominant CPEG in pneumonia-causing MEM-R A. baumannii isolates. Conclusions: After deliberative estimations, dosages of 200 mg minocycline intravenously every 12 h (SBP, 8 mg/L), 100 mg tigecycline intravenously every 12 h (SBP, 1 mg/L), and 160 mg nebulized colistin methanesulphonate every 8 h (SBP, 2 mg/L) are needed for the effective treatment of pneumonia-causing MEM-R A. baumannii isolates. |
| first_indexed | 2024-03-07T16:22:57Z |
| format | Article |
| id | doaj.art-b7e6504839cd4dc199b1241fa83661aa |
| institution | Directory Open Access Journal |
| issn | 2213-7165 |
| language | English |
| last_indexed | 2024-04-24T20:26:11Z |
| publishDate | 2024-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Global Antimicrobial Resistance |
| spelling | doaj.art-b7e6504839cd4dc199b1241fa83661aa2024-03-22T05:39:35ZengElsevierJournal of Global Antimicrobial Resistance2213-71652024-03-0136411418In vitro antimicrobial susceptibility data of global meropenem-resistant Acinetobacter baumannii isolates causing pneumonia: Data from the Antimicrobial Testing Leadership and Surveillance Program, 2014–2021, and re-estimations of susceptibility breakpoints and appropriate dosages of important antibiotics for pneumonia treatmentShun-Chung Hsueh0Yu-Tsung Huang1Wen-Chien Ko2I-Min Liu3Po-Chuen Hsieh4Shio-Shin Jean5Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, TaiwanDepartment of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan; Department of Laboratory Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, TaiwanDepartment of Medicine, College of Medicine, National Cheng Kung University, Tainan, TaiwanDepartment of Pharmacy, College of Pharmacy and Health Care, Tajen University, Pingtung, TaiwanDepartment of Pharmacy, College of Pharmacy and Health Care, Tajen University, Pingtung, TaiwanDepartment of Pharmacy, College of Pharmacy and Health Care, Tajen University, Pingtung, Taiwan; Departments of Internal Medicine and Critical Care Medicine, Min-Sheng General Hospital, Taoyuan, Taiwan; Corresponding author. Mailing address: Departments of Internal Medicine and Critical Care Medicine, Min-Sheng General Hospital, No. 168, Ching-Kuo Rd, 330 Taoyuan City, Taiwan.ABSTRACT: Objectives: To evaluate the susceptibility of globally pneumonia-causing meropenem-resistant (MEM-R) Acinetobacter baumannii isolates against important antibiotics and estimate appropriate dosages of indicated antibiotics. Methods: We extracted the 2014–2021 Antimicrobial Testing of Leadership Surveillance database regarding the susceptibility of MEM-R A. baumannii isolates causing pneumonia against important antibiotics. The susceptibility and carbapenemase-encoding gene (CPEG) data of pneumonia-causing MEM-R A. baumannii isolates from patients hospitalized in intensive care units of five major regions were analyzed. The susceptibility breakpoints (SBP) recommended by the Clinical and Laboratory Standards Institute (CLSI) in 2022, other necessary criteria [SBP of MIC for colistin, 2 mg/L, in the CLSI 2018; and cefoperazone-sulbactam (CFP-SUL), 16 mg/L], and the pharmacokinetic and pharmacodynamic data of indicated antibiotics were employed. Results: Applying the aforementioned criteria, we observed the susceptible rates of colistin, minocycline, and CFP-SUL against the pneumonia-causing MEM-R A. baumannii isolates globally (n = 2905) were 93.2%, 69.1%, and 26.3%, respectively. Minocycline was significantly more active in vitro (MIC ≤4 mg/L) against the pneumonia-causing MEM-R A. baumannii isolates collected from North and South America compared to those from other regions (>90% vs. 58–72%). Additionally, blaOXA-23 and blaOXA-72 were the predominant CPEG in pneumonia-causing MEM-R A. baumannii isolates. Conclusions: After deliberative estimations, dosages of 200 mg minocycline intravenously every 12 h (SBP, 8 mg/L), 100 mg tigecycline intravenously every 12 h (SBP, 1 mg/L), and 160 mg nebulized colistin methanesulphonate every 8 h (SBP, 2 mg/L) are needed for the effective treatment of pneumonia-causing MEM-R A. baumannii isolates.http://www.sciencedirect.com/science/article/pii/S2213716524000249Susceptibility breakpointMeropenem-resistantAcinetobacter baumanniiColistinMinocyclineTigecycline |
| spellingShingle | Shun-Chung Hsueh Yu-Tsung Huang Wen-Chien Ko I-Min Liu Po-Chuen Hsieh Shio-Shin Jean In vitro antimicrobial susceptibility data of global meropenem-resistant Acinetobacter baumannii isolates causing pneumonia: Data from the Antimicrobial Testing Leadership and Surveillance Program, 2014–2021, and re-estimations of susceptibility breakpoints and appropriate dosages of important antibiotics for pneumonia treatment Journal of Global Antimicrobial Resistance Susceptibility breakpoint Meropenem-resistant Acinetobacter baumannii Colistin Minocycline Tigecycline |
| title | In vitro antimicrobial susceptibility data of global meropenem-resistant Acinetobacter baumannii isolates causing pneumonia: Data from the Antimicrobial Testing Leadership and Surveillance Program, 2014–2021, and re-estimations of susceptibility breakpoints and appropriate dosages of important antibiotics for pneumonia treatment |
| title_full | In vitro antimicrobial susceptibility data of global meropenem-resistant Acinetobacter baumannii isolates causing pneumonia: Data from the Antimicrobial Testing Leadership and Surveillance Program, 2014–2021, and re-estimations of susceptibility breakpoints and appropriate dosages of important antibiotics for pneumonia treatment |
| title_fullStr | In vitro antimicrobial susceptibility data of global meropenem-resistant Acinetobacter baumannii isolates causing pneumonia: Data from the Antimicrobial Testing Leadership and Surveillance Program, 2014–2021, and re-estimations of susceptibility breakpoints and appropriate dosages of important antibiotics for pneumonia treatment |
| title_full_unstemmed | In vitro antimicrobial susceptibility data of global meropenem-resistant Acinetobacter baumannii isolates causing pneumonia: Data from the Antimicrobial Testing Leadership and Surveillance Program, 2014–2021, and re-estimations of susceptibility breakpoints and appropriate dosages of important antibiotics for pneumonia treatment |
| title_short | In vitro antimicrobial susceptibility data of global meropenem-resistant Acinetobacter baumannii isolates causing pneumonia: Data from the Antimicrobial Testing Leadership and Surveillance Program, 2014–2021, and re-estimations of susceptibility breakpoints and appropriate dosages of important antibiotics for pneumonia treatment |
| title_sort | in vitro antimicrobial susceptibility data of global meropenem resistant acinetobacter baumannii isolates causing pneumonia data from the antimicrobial testing leadership and surveillance program 2014 2021 and re estimations of susceptibility breakpoints and appropriate dosages of important antibiotics for pneumonia treatment |
| topic | Susceptibility breakpoint Meropenem-resistant Acinetobacter baumannii Colistin Minocycline Tigecycline |
| url | http://www.sciencedirect.com/science/article/pii/S2213716524000249 |
| work_keys_str_mv | AT shunchunghsueh invitroantimicrobialsusceptibilitydataofglobalmeropenemresistantacinetobacterbaumanniiisolatescausingpneumoniadatafromtheantimicrobialtestingleadershipandsurveillanceprogram20142021andreestimationsofsusceptibilitybreakpointsandappropriatedosagesofimportan AT yutsunghuang invitroantimicrobialsusceptibilitydataofglobalmeropenemresistantacinetobacterbaumanniiisolatescausingpneumoniadatafromtheantimicrobialtestingleadershipandsurveillanceprogram20142021andreestimationsofsusceptibilitybreakpointsandappropriatedosagesofimportan AT wenchienko invitroantimicrobialsusceptibilitydataofglobalmeropenemresistantacinetobacterbaumanniiisolatescausingpneumoniadatafromtheantimicrobialtestingleadershipandsurveillanceprogram20142021andreestimationsofsusceptibilitybreakpointsandappropriatedosagesofimportan AT iminliu invitroantimicrobialsusceptibilitydataofglobalmeropenemresistantacinetobacterbaumanniiisolatescausingpneumoniadatafromtheantimicrobialtestingleadershipandsurveillanceprogram20142021andreestimationsofsusceptibilitybreakpointsandappropriatedosagesofimportan AT pochuenhsieh invitroantimicrobialsusceptibilitydataofglobalmeropenemresistantacinetobacterbaumanniiisolatescausingpneumoniadatafromtheantimicrobialtestingleadershipandsurveillanceprogram20142021andreestimationsofsusceptibilitybreakpointsandappropriatedosagesofimportan AT shioshinjean invitroantimicrobialsusceptibilitydataofglobalmeropenemresistantacinetobacterbaumanniiisolatescausingpneumoniadatafromtheantimicrobialtestingleadershipandsurveillanceprogram20142021andreestimationsofsusceptibilitybreakpointsandappropriatedosagesofimportan |